Across TCGA pan-cancer cohorts, ST6GALNAC5 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated ST6GALNAC5 data layer compared with 25 for mass-spec protein and 5 for mutation status.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ST6GALNAC5 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ST6GALNAC5 expression acts as an unfavorable survival marker.
LUAD are the cancer types where ST6GALNAC5 mass-spec protein most reproducibly stratifies survival.